|
Leucovorin for the Treatment of 5 q Minus Syndrome Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Leucovorin for the Treatment of 5 q Minus Syndrome conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Leucovorin for the Treatment of 5 q Minus Syndrome Clinical research trials and Leucovorin for the Treatment of 5 q Minus Syndrome health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Leucovorin for the Treatment of 5 q Minus Syndrome. Leucovorin for the Treatment of 5 q Minus Syndrome Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Leucovorin for the Treatment of 5 q Minus Syndrome clinical trial. Test subjects typically receive the most expert healthcare available for their Leucovorin for the Treatment of 5 q Minus Syndrome condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Leucovorin for the Treatment of 5 q Minus Syndrome  Leucovorin for the Treatment of 5 q Minus Syndrome
Leucovorin for the Treatment of 5 q Minus Syndrome
For Condition: 5q Minus Syndrome,Myelodysplastic Syndrome
Status: Completed
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: The 5 q minus syndrome is a condition that occurs due to a missing segment of chromosome 5 in the normal genetic make-up of the cells responsible for forming blood cells. The condition causes patients to have the inability to make blood normally. Many patients with this syndrome need transfusions of red blood cells, platelets, and/or white blood cells. Low levels of platelets may cause the patient to bleed easily and low levels of whit blood cells make the patient susceptible to infections. A small number of patients with 5 q minus syndrome develop leukemia, which is often untreatable with chemotherapy. Researchers believe that one of the genes missing in 5 q minus syndrome is the gene responsible for making folic acid active in the body. Folic acid is a vitamin required for normal blood production. The purpose of this study to test the effectiveness of a drug called leucovorin for the treatment of 5 q minus syndrome. Leucovorin is an active form of the vitamin folic acid that does not require the missing genes to activate it. Patients participating in this study may or may not improve with leucovorin treatment. However, the study will improve researchers understanding of the disease and may lead other potential therapies for the disease.
Details: The objective of this protocol is to determine whether leucovorin treatment can normalize hematopoietic cell growth and differentiation in patients with 5q- syndrome which may lack the gene for dihydrofolate reductase enzyme.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: All patients 18 years old and older with RA, RARS and RAEB who have a 5q deletion as their sole cytogenetic abnormality who require transfusion support with blood defined as needing at least one unit of packed red blood cells per month for greater than or equal to 2 months and/or thrombocytopenia defined as a platelet count less than 50,000, and/or severe neutropenia (absolute neutrophil count less than 500) are eligible, including patients that had been treated with chemotherapy or experimental agents such as retinoids, phenylbutyrate, amifostine, Vitamin D, ATG or hematopoietic growth factors. Patients must not be transforming to acute leukemia (greater than 20% blasts in marrow aspirate). Patients must not have had treatment with growth factors or any other experimental drug within 4 weeks prior to entry on protocol. Patients must not have an ECOG performance status greater than 2. Patients must not have an active uncontrolled infection. No patients for whom bone marrow transplant is indicated as primary therapy. Must be able to give informed consent. Patients must not be HIV positive. Patients must not be pregnant.
Total Enrollment: 14
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980101; 98-CC-0101
Study Start Date: April 24, 1998
Record last reviewed: July 29, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004997
Other 5q Minus Syndrome Studies:
1. The Role of Cyclosporin in Blood Cell Transplants with T-Cell Add-Back for Blood Cancers
2. Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia
3. Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
4. Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
5. Megadose CD34 Selected Progenitor Cells for Transplantation in Patients with Advanced Hematological Malignant Diseases
Related Studies:
Other 5q Minus Syndrome Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Leucovorin for the Treatment of 5 q Minus Syndrome
|
|
|
|
|
|
|
|
